Compare Starbucks Corp (SBUX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Sanofi SA — how do they compare? Starbucks Corp trades at $100.23 (market cap $114.05B), while Sanofi SA trades at $43.12 (market cap $103.41B). The key difference: Starbucks Corp and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.65%). Which is the better fit depends on your goals.
| SBUX | SNY | |
|---|---|---|
Market Cap | $114.05B | $103.41B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $52.34 |
52-Week Low | $78.46 | $41.33 |
Enterprise Value | $132.87B | $123.44B |
Dividend Yield | 2.48% | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $102.01, down 2.35% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish momentum in moving averages but recent earnings beats in Q1 and Q2 2026 highlight operational progress. Revenue reached $37.18B in 2025, though net income margin compressed to 5.17%. Analyst consensus is a Buy with a $113.60 price target, but high P/E of 58.97 suggests premium valuation. Recent news emphasizes CEO Niccol's turnaround efforts and union-related legal developments.
The outlook balances earnings momentum against valuation concerns. Upside hinges on margin recovery and sustained comp sales growth, but risks include labor disputes, high debt, and competitive pressures. Institutional sentiment is cautiously optimistic, with 47.46% of analysts rating Buy.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
